Closing Deliveries by Buyer. At the Closing, Buyer shall deliver to Seller: (a) the Closing Payment by wire transfer of immediately available funds into an account (or accounts) designated in advance by Seller; (b) a counterpart of the Assignment and Assumption Agreement, duly executed by Buyer; (c) a counterpart of the Xxxx of Sale, duly executed by Buyer; (d) a counterpart of the IP Assignment Agreement, duly executed by Buyer; (e) a counterpart of the Transition Services Agreement, duly executed by Seller; and (f) a letter to the FDA, substantially in the form attached hereto as Exhibit I-2 (the “Buyer FDA Letter”), executed by Buyer, accepting the transfer of the Product NDA to Buyer.
Appears in 3 contracts
Samples: Asset Purchase Agreement (Journey Medical Corp), Asset Purchase Agreement (Journey Medical Corp), Asset Purchase Agreement (Fortress Biotech, Inc.)
Closing Deliveries by Buyer. At the Closing, Buyer shall deliver to Seller:
(a) no later than 12 p.m. ET on the date following the Closing Date, the Closing Payment by wire transfer of immediately available funds into an account (or accounts) designated in advance by Seller;
(b) a counterpart of the Assignment and Assumption Agreement, duly executed by Buyer;
(c) a counterpart of the Xxxx of Sale, duly executed by Buyer;
(d) a counterpart of the IP Assignment Agreement, duly executed by Buyer;
(e) a counterpart of the Transition Services Agreement, duly executed by Seller; and
(f) a letter to the FDA, substantially in the form attached hereto as Exhibit I-2 F-2 (the “Buyer FDA Letter”), executed by Buyer, accepting the transfer of the Product NDA NDAs to Buyer. .
Appears in 1 contract
Closing Deliveries by Buyer. At the Closing, Buyer shall deliver to Seller:
(a) the Closing Payment by wire transfer of immediately available funds into an account (or accounts) designated in advance by Seller;
(b) a counterpart of the Assignment and Assumption Agreement, duly executed by Buyer;
(c) a counterpart of the Xxxx Bxxx of Sale, duly executed by Buyer;
(d) a counterpart of the IP Assignment Agreement, duly executed by Buyer;
(e) a counterpart of the Transition Services Agreement, duly executed by Seller; and
(f) a letter to the FDA, substantially in the form attached hereto as Exhibit I-2 F-2 (the “Buyer FDA Letter”), executed by Buyer, accepting the transfer of the Product NDA NDAs to Buyer. .
Appears in 1 contract
